Precision Oncology News reports that ctDNA methylation profiles may help diagnose colorectal cancer and predict prognosis — and that Laboratory for Advanced Medicine [now Helio Genomics] is commercializing the test.
Featured in Precision Oncology News (GenomeWeb).
Precision Oncology News reported that the methylation profiles of circulating tumor DNA (ctDNA) may help diagnose colorectal cancer and predict patient prognosis — potentially forming the basis of a new, less invasive cancer test. Researchers led by Sun Yat-sen University Cancer Center’s Rui-hua Xu reported the findings in Science Translational Medicine.
The report notes that Irvine, California-based Laboratory for Advanced Medicine [now Helio Genomics], which focuses on developing liquid biopsy tests for cancer, is commercializing the test, and that the work is contributing to the development of its next commercial cancer test.
The team compared methylation profiles for 459 colorectal cancer tumor samples and 754 normal samples, homing in on nine markers to construct a diagnostic “cd-score” with nearly 88% sensitivity and almost 90% specificity. A prognostic “cp-score” separated patients into high- and low-risk survival groups. One marker, cg10673833, identified 19 of 21 colorectal cancers and seven of eight cancers in situ in a high-risk cohort of 1,493 individuals — a sensitivity of 89.7% and specificity of 86.8%.
The underlying study is listed among our publications.
Source: Precision Oncology News. Read the full article.